Home Cart Sign in  
Chemical Structure| 389-08-2 Chemical Structure| 389-08-2
Chemical Structure| 389-08-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nalidixic acid, synthetic 1,8-naphthyridine, is a spectrum antimicrobial agent.

Synonyms: NSC 82174; WIN 18,320; Nalidixic Acid, Nevigramon, Neggram, Wintomylon, WIN 18,320

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Boyao Zhang ; George-Eugen Maftei ; Bartosz Bartmanski ; Michael Zimmermann ;

Abstract: Organic carcinogens, in particular DNA-reactive compounds, contribute to the irreversible initiation step of tumorigenesis through introduction of genomic instability. Although carcinogen bioactivation and detoxification by human enzymes has been extensively studied, carcinogen biotransformation by human-associated bacteria, the microbiota, has not yet been systematically investigated. We tested the biotransformation of 68 mutagenic carcinogens by 34 bacterial species representative for the upper and lower human gastrointestinal tract and found that the majority (41) of the tested carcinogens undergo bacterial biotransformation. To assess the functional consequences of microbial carcinogen metabolism, we developed a pipeline to couple gut bacterial carcinogen biotransformation assays with Ames mutagenicity testing and liver biotransformation experiments. This revealed a bidirectional crosstalk between gut microbiota and host carcinogen metabolism, which we validated in gnotobiotic mouse models. Overall, the systematic assessment of gut microbiota carcinogen biotransformation and its interplay with host metabolism highlights the gut microbiome as an important modulator of exposome-induced tumorigenesis.

Alternative Products

Product Details of Nalidixic acid

CAS No. :389-08-2
Formula : C12H12N2O3
M.W : 232.24
SMILES Code : O=C(C1=CN(CC)C2=C(C=CC(C)=N2)C1=O)O
Synonyms :
NSC 82174; WIN 18,320; Nalidixic Acid, Nevigramon, Neggram, Wintomylon, WIN 18,320
MDL No. :MFCD00006884
InChI Key :MHWLWQUZZRMNGJ-UHFFFAOYSA-N
Pubchem ID :4421

Safety of Nalidixic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H351-H361
Precautionary Statements:P280-P305+P351+P338

Application In Synthesis of Nalidixic acid

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 389-08-2 ]

[ 389-08-2 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 7304-32-7 ]
  • [ 35737-10-1 ]
  • [ 129397-83-7 ]
  • [ 389-08-2 ]
  • Fmoc-D-α-amino-4-(protected)-aminobutyric acid [ No CAS ]
  • 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid [(7S,10R)-10-(2-amino-ethyl)-7-benzyl-9,12,16-trioxo-7,8,9,10,11,12,13,14,15,16-decahydro-6H-5-oxa-8,11,15-triaza-benzocyclotetradecen-2-yl]-amide [ No CAS ]
  • 2
  • [ 7304-32-7 ]
  • [ 35737-10-1 ]
  • [ 129397-83-7 ]
  • [ 389-08-2 ]
  • Fmoc-L-α-amino-4-(protected)-aminobutyric acid [ No CAS ]
  • 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid [(7S,10S)-10-(2-amino-ethyl)-7-benzyl-9,12,16-trioxo-7,8,9,10,11,12,13,14,15,16-decahydro-6H-5-oxa-8,11,15-triaza-benzocyclotetradecen-2-yl]-amide [ No CAS ]
  • 3
  • [ 934343-42-7 ]
  • [ 50-00-0 ]
  • [ 6642-30-4 ]
  • [ 389-08-2 ]
 

Historical Records

Categories